<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01728389</url>
  </required_header>
  <id_info>
    <org_study_id>IBT-COI-01</org_study_id>
    <nct_id>NCT01728389</nct_id>
  </id_info>
  <brief_title>Intrabone Transplantation of Allogenic Peripheral Blood Stem Cells in Patients With Myeloid and Lymphoid Malignancies.</brief_title>
  <official_title>Efficacy and Safety of Direct Intrabone Transplantation of Peripheral Blood Haematopoietic Stem Cells Form HLA-matched Sibling Donors in Patients With Myeloid and Lymphoid Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maria Sklodowska-Curie Institute - Oncology Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate efficacy and safety of direct intrabone
      transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched
      sibling donors in patients with myeloid and lymphoid malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogenic haematopoietic stem cell transplantation is an established treatment option for
      haematologic malignancies, especially leukaemias and lymphomas, providing curative potential.
      The optimal donor is HLA-matched sibling and G-CSF stimulated peripheral blood is nowadays
      the most common source of stem cells. Routinely used route of stem cell transplantation is
      intravenous infusion via central venous catheter. Based on the animal studies, only 10-15% of
      intravenously transplanted stem cells migrate to haematopoietic sites while the rest is lost
      in other organs. Results of studies of direct intrabone allogenic cord-blood cells
      transplantation in humans confirm that this route of transplantation is associated with less
      probability of graft failure and moreover may reduce risk of graft-versus-host disease and
      malignancy relapse. For those purposes in the current study we investigate intrabone route of
      allogenic peripheral blood stem cell transplantation. Our intention is to achieve fast
      engraftment and minimize risk of relapse and graft graft-versus-host disease.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neutrophil engraftment (ANC &gt; 0,5 G/l)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lineage chimerism of peripheral blood T-cell lymphocytes</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet engraftment (Plt &gt; 20 G/l)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions related with intrabone transplantation procedure</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Relapse incidence</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Graft-versus-host disease incidence</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Intrabone transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intrabone transplantation</intervention_name>
    <description>Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.</description>
    <arm_group_label>Intrabone transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-55 years

          -  Diagnosis of leukaemia or lymphoma

          -  Indication for allogenic stem cell transplantation according to European Group for
             Blood and Marrow Transplantation guidelines

          -  HLA-matched sibling donor qualified for peripheral blood stem cell donation

          -  Performance status WHO 0-1

          -  Written informed consent

        Exclusion Criteria:

          -  Organ dysfunction: elevated ALT, AST, bilirubin, AF; creatinine &gt;1.5 upper normal
             limit; LVEF &lt;45%

          -  Active infection

          -  Unstable diabetes

          -  Psychiatric diseases

          -  Obesity or anatomical obstacle for direct intrabone transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomasz Czerw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tomasz Czerw, MD</last_name>
    <phone>+48 32 2788523</phone>
    <email>tomcmed@poczta.onet.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sebastian Giebel, MD</last_name>
    <phone>+48 32 2788523</phone>
    <email>sgiebel@io.gliwice.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MSC Memorial CAncer Center and Institute of Oncology</name>
      <address>
        <city>Gliwice</city>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Giebel, Assoc. prof.</last_name>
      <phone>+48322788523</phone>
      <email>ots@io.gliwice.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Frassoni F, Gualandi F, Podestà M, Raiola AM, Ibatici A, Piaggio G, Sessarego M, Sessarego N, Gobbi M, Sacchi N, Labopin M, Bacigalupo A. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol. 2008 Sep;9(9):831-9. doi: 10.1016/S1470-2045(08)70180-3. Epub 2008 Aug 8.</citation>
    <PMID>18693069</PMID>
  </reference>
  <reference>
    <citation>Okada M, Yoshihara S, Taniguchi K, Kaida K, Ikegame K, Kato R, Tamaki H, Inoue T, Soma T, Kai S, Kato S, Ogawa H. Intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning treatment: a phase I study. Biol Blood Marrow Transplant. 2012 Apr;18(4):633-9. doi: 10.1016/j.bbmt.2011.08.010. Epub 2011 Aug 23.</citation>
    <PMID>21867667</PMID>
  </reference>
  <reference>
    <citation>Massollo M, Podestà M, Marini C, Morbelli S, Cassanelli C, Pinto V, Ubezio G, Curti G, Uccelli A, Frassoni F, Sambuceti G. Contact with the bone marrow microenvironment readdresses the fate of transplanted hematopoietic stem cells. Exp Hematol. 2010 Oct;38(10):968-77. doi: 10.1016/j.exphem.2010.06.003. Epub 2010 Jun 13.</citation>
    <PMID>20550953</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2012</study_first_submitted>
  <study_first_submitted_qc>November 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2012</study_first_posted>
  <last_update_submitted>July 23, 2013</last_update_submitted>
  <last_update_submitted_qc>July 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allogenic stem cell transplantation</keyword>
  <keyword>peripheral blood stem cells</keyword>
  <keyword>intrabone</keyword>
  <keyword>intra-bone</keyword>
  <keyword>leukemia</keyword>
  <keyword>lymphoma</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

